John G. Golfinos

About

John G. Golfinos, MD, is a professor in the Department of Neurosurgery at NYU Grossman School of Medicine and also holds a professorship in the Department of Otolaryngology-Head and Neck Surgery at the same institution. He is the Gray Foundation Chair of Neurosurgery, Co-Director of the Brain Tumor Center at Perlmutter Cancer Center, and Chair of the Department of Neurosurgery. Dr. Golfinos specializes in neurosurgery with a focus on brain tumors, including benign and cancerous tumors that can occur in the brain. He has devoted a significant part of his career to researching neurofibromatosis type 2, a genetic disease that causes complex tumors to grow in the brain and spinal cord, affecting nerves responsible for hearing and balance. He is also at the forefront of stereotactic surgery, which allows for precise viewing and removal of brain tumors during surgery. Dr. Golfinos has been recognized as one of America's top doctors by Castle Connolly for more than 10 years. He is the founder of NYU Langone Gamma Knife Radiosurgery and has contributed extensively to the field of neurosurgery through his research and clinical practice.

Research topics

• Medicine
• Internal medicine
• Biology
• Pathology
• Oncology
• Genetics
• Medical physics
• Cancer research
• Radiology
• Bioinformatics

Selected publications

• Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging

  Nature Medicine · 2023 · 161 citations

  DOI

• Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated

  Journal of Clinical Oncology · 2021 · 134 citations

  PURPOSE: Meningiomas are the most frequent primary intracranial tumors. Patient outcome varies widely from benign to highly aggressive, ultimately fatal courses. Reliable identification of risk of progression for individual patients is of pivotal importance. However, only biomarkers for highly aggressive tumors are established (CDKN2A/B and TERT), whereas no molecularly based stratification exists for the broad spectrum of patients with low- and intermediate-risk meningioma. METHODS: DNA methyla…

  DOI

• Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing

  Neuro-Oncology Advances · 2023 · 33 citations

  Background: Central nervous system (CNS) cancer is the 10th leading cause of cancer-associated deaths for adults, but the leading cause in pediatric patients and young adults. The variety and complexity of histologic subtypes can lead to diagnostic errors. DNA methylation is an epigenetic modification that provides a tumor type-specific signature that can be used for diagnosis. Methods: We performed a prospective study using DNA methylation analysis as a primary diagnostic method for 1921 brain…

  PublisherOA PDFDOI

• Hypofractionation of Gamma Knife Radiosurgery for Intracranial Meningiomas: A Retrospective Multicenter Study and Systematic Review of Literature

  Neurosurgery · 2025-10-27 · 1 citations

  article

  BACKGROUND AND OBJECTIVES: Hypofractionated Gamma Knife radiosurgery (hfGKRS) is increasingly considered for treating large or near-critical structure meningiomas because of potential safety advantages. However, data on optimal fractionation and long-term outcomes remain limited. This study evaluated the longer-term tumor control and toxicity after hfGKRS for intracranial meningiomas at 2 large centers, supplemented by a systematic review and meta-analysis of existing literature. METHODS: The an…

  PublisherDOI

• P04.07.A AI-BASED NUCLEAR MORPHOMETRY REVEALS DISTINCT MORPHOLOGICAL PATTERNS BETWEEN IDH-MUTANT, IDH-WILDTYPE, AND NON-TUMOROUS CELLS IN STIMULATED RAMAN HISTOLOGY

  Neuro-Oncology · 2025-10-01 · 1 citations

  articleOpen access

  Abstract BACKGROUND Isocitrate dehydrogenase (IDH) mutation status significantly influences diffuse glioma classification. While molecular testing remains the gold standard, we investigated whether cell nuclear morphology in virtual H&E-like images of diffuse gliomas and non-tumorous tissues represents a critical feature category that could serve as a foundation for AI-based single-cell molecular subtyping using label-free Stimulated Raman Histology (SRH). MATERIAL AND METHODS Label-free and…

  PublisherOA PDFDOI

Frequent coauthors

• Matija Snuderl

  New York University

  134 shared

• David Zagzag

  134 shared

• Douglas Kondziolka

  New York University

  112 shared

• Dimitris G. Placantonakis

  NYU Langone’s Laura and Isaac Perlmutter Cancer Center

  88 shared

• J. Thomas Roland

  NYU Langone Health

  76 shared

• Donato Pacione

  NYU Langone Health

  70 shared

• Meng Law

  Monash University

  64 shared

• Matthias A. Karajannis

  Memorial Sloan Kettering Cancer Center

  64 shared

Awards & honors

• Named one of America’s top doctors by Castle Connolly for mo…

Similar researchers at New York University

• Margaret E. Riceh-66
• Chandra Senh-62